Deborah Lang, PhD

Associate Professor, Dermatology

Deborah Lang
617.638.5500
609 Albany Street

Biography

Dr. Lang, appointed as an Associate Professor of Dermatology, was recruited from the University of Chicago. Here at BU, she will continue her basic science research mission focusing on the molecular and cellular biology of melanoma. The lab’s research is centered on studying processes that occur during pigment cell development of the embryo and applying these findings toward melanoma. The premise is that pathways that are essential for development (such as growth, survival, and migration) are also important for melanoma progression (over-growth, inappropriate survival, and metastasis). She has mentored over twenty students and has served as an elected council member and plenary speaker of the Pan American Society for Pigment Cell Research.

Other Positions

  • Member, BU-BMC Cancer Center, Boston University

Education

  • Drexel University College of Medicine, PhD
  • Philadelphia University, BS

Publications

  • Published on 6/29/2022

    Vittoria MA, Kingston N, Kotynkova K, Xia E, Hong R, Huang L, McDonald S, Tilston-Lunel A, Darp R, Campbell JD, Lang D, Xu X, Ceol CJ, Varelas X, Ganem NJ. Inactivation of the Hippo tumor suppressor pathway promotes melanoma. Nat Commun. 2022 Jun 29; 13(1):3732. PMID: 35768444.

    Read at: PubMed
  • Published on 12/29/2021

    Huang L, Zhai Y, Fajardo CD, Lang D. YK-4-279 Attenuates Progression of Pre-Existing Pigmented Lesions to Nodular Melanoma in a Mouse Model. Cancers (Basel). 2021 Dec 29; 14(1). PMID: 35008307.

    Read at: PubMed
  • Published on 9/1/2021

    Lui JW, Moore SPG, Huang L, Ogomori K, Li Y, Lang D. YAP facilitates melanoma migration through regulation of actin-related protein 2/3 complex subunit 5 (ARPC5). Pigment Cell Melanoma Res. 2022 01; 35(1):52-65. PMID: 34468072.

    Read at: PubMed
  • Published on 2/1/2021

    Huang L, Zhai Y, La J, Lui JW, Moore SPG, Little EC, Xiao S, Haresi AJ, Brem C, Bhawan J, Lang D. Targeting Pan-ETS Factors Inhibits Melanoma Progression. Cancer Res. 2021 04 15; 81(8):2071-2085. PMID: 33526511.

    Read at: PubMed
  • Published on 9/10/2019

    Zhai Y, Haresi AJ, Huang L, Lang D. Differences in tumor initiation and progression of melanoma in the BrafCA ;Tyr-CreERT2;Ptenf/f model between male and female mice. Pigment Cell Melanoma Res. 2020 01; 33(1):119-121. PMID: 31449725.

    Read at: PubMed
  • Published on 1/1/2019

    Lui JW, Xiao S, Ogomori K, Hammarstedt JE, Little EC, Lang D. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma. J Cancer. 2019; 10(1):1-10. PMID: 30662519.

    Read at: PubMed
  • Published on 3/29/2017

    Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D. Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncol Lett. 2017 Jun; 13(6):4027-4034. PMID: 28588695.

    Read at: PubMed
  • Published on 9/1/2015

    Kubic JD, Little EC, Kaiser RS, Young KP, Lang D. FOXD3 Promotes PAX3 Expression in Melanoma Cells. J Cell Biochem. 2016 Feb; 117(2):533-41. PMID: 26252164.

    Read at: PubMed
  • Published on 7/23/2015

    Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem. 2015 Sep 04; 290(36):21901-14. PMID: 26205821.

    Read at: PubMed
  • Published on 12/22/2014

    Kubic JD, Little EC, Lui JW, Iizuka T, Lang D. PAX3 and ETS1 synergistically activate MET expression in melanoma cells. Oncogene. 2015 Sep 17; 34(38):4964-74. PMID: 25531327.

    Read at: PubMed

View 22 more publications: View full profile at BUMC

View all profiles